MktsMarkets

Xenetic Biosciences, Inc.
NASDAQ: XBIOKey statistics
XBIO News
Stories mentioning XBIO from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 807.00 | 766.00 | 1,027 | 590.00 | 593.00 | 649.00 | 614.00 | 726.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 661.00 | 773.00 | 756.00 | 657.00 | 879.00 | 1,042 | 368.00 | 934.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 1,309 | 1,389 | 1,572 | 1,314 | 1,536 | 1,748 | 1,114 | 2,064 |
| Operating Income (Loss) | (502.00) | (624.00) | (545.00) | (724.00) | (942.00) | (1,100) | (499.00) | (1,337) |
| Interest Income | 46.00 | 39.00 | ||||||
| Interest Expense | ||||||||
| Other Expense | 0.00 | 1.00 | 4.00 | 1.00 | 0.00 | (8.00) | 2.00 | 0.00 |
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (456.00) | (579.00) | (510.00) | (689.00) | (903.00) | (1,054) | (437.00) | (1,274) |
| Earnings Per Share (Basic) | (0.20) | (0.34) | (0.33) | (0.45) | (0.59) | (0.68) | (0.28) | (0.83) |
| Earnings Per Share (Diluted) | (0.20) | (0.34) | (0.33) | (0.45) | (0.59) | (0.68) | (0.28) | (0.83) |
| Weighted Average Shares Outstanding (Basic) | 2,291 | 1,702 | 1,542 | 1,542 | 1,542 | 1,541 | 1,542 | 1,541 |
| Weighted Average Shares Outstanding (Diluted) | 2,291 | 1,702 | 1,542 | 1,542 | 1,542 | 1,541 | 1,542 | 1,541 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About XBIO
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a stock listed on the Nasdaq Stock Market under the ticker symbol XBIO. It last traded at $1.82 (Oct 26, 2026, 2:08 PM ET), up 5.8% on the day. That gives Xenetic Biosciences a market capitalisation of $4.5M.
Over the past 52 weeks XBIO has traded between $1.72 and $4.94.
Revenue for the quarter ended Mar 31, 2026 was $807.0K; a net loss of $456.0K. Revenue was up 36.1% from $593.0K in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $807.0K | -$456.0K | -56.5% |
| Dec 31, 2025 | $766.0K | -$579.0K | -75.6% |
| Sep 30, 2025 | $1.0M | -$510.0K | -49.7% |
| Jun 30, 2025 | $590.0K | -$689.0K | -116.8% |
From Xenetic Biosciences’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…